Bulletin
Investor Alert

Market Pulse Archives

Aug. 5, 2020, 8:39 a.m. EDT

J&J to receive $1 billion in U.S. funding to make 100 million doses of its COVID-19 vaccine

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

  • X
    Johnson & Johnson (JNJ)
  • X
    S&P 500 Index (SPX)

or Cancel Already have a watchlist? Log In

By Jaimy Lee

Shares of Johnson & Johnson /zigman2/quotes/201724570/composite JNJ +0.22% gained 0.8% in premarket trading on Wednesday after the company said it will receive more than $1 billion from the U.S. government to manufacture 100 million doses of its investigational COVID-19 vaccine. The vaccine will be provided at a "global not-for-profit basis for emergency pandemic use," J&J said. The company's vaccine candidate recently entered the Phase 1/2a clinical trial, which is taking place in Belgium and the U.S. J&J's stock is up 0.9% year-to-date, while the S&P 500 /zigman2/quotes/210599714/realtime SPX +0.47% has gained 2.3%.

/zigman2/quotes/201724570/composite
US : U.S.: NYSE
$ 164.08
+0.36 +0.22%
Volume: 6.72M
Oct. 25, 2021 4:00p
P/E Ratio
24.52
Dividend Yield
2.58%
Market Cap
$430.99 billion
Rev. per Employee
$613,918
loading...
/zigman2/quotes/210599714/realtime
US : S&P US
4,566.48
+21.58 +0.47%
Volume: 1.85B
Oct. 25, 2021 5:26p
loading...

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »

Partner Center

Link to MarketWatch's Slice.